tiprankstipranks
Advertisement
Advertisement

HK:6622 Stock Latest News

Zhaoke Ophthalmology Secures Global Rights to Pediatric Myopia Drug NVK002
Company AnnouncementsZhaoke Ophthalmology Secures Global Rights to Pediatric Myopia Drug NVK002
5d ago
6622
Zhaoke Ophthalmology Wins Boao Approval for First Innovative Presbyopia Drug in China
PremiumCompany Announcements
Zhaoke Ophthalmology Wins Boao Approval for First Innovative Presbyopia Drug in China
12d ago
6622
Zhaoke Ophthalmology’s Myopia Drug NVK002 Accepted for Australian TGA Evaluation
PremiumCompany Announcements
Zhaoke Ophthalmology’s Myopia Drug NVK002 Accepted for Australian TGA Evaluation
1M ago
6622
Zhaoke Ophthalmology Launches HK$100 Million Share Buy-Back Plan
PremiumCompany Announcements
Zhaoke Ophthalmology Launches HK$100 Million Share Buy-Back Plan
1M ago
6622
Zhaoke Ophthalmology Strikes Indonesia Distribution Deal for Dry Eye Gel
PremiumCompany Announcements
Zhaoke Ophthalmology Strikes Indonesia Distribution Deal for Dry Eye Gel
1M ago
6622
Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM
PremiumCompany AnnouncementsZhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM
2M ago
6622
Zhaoke Ophthalmology Renews Related-Party CMO Deal for Eyprotor
Premium
Company Announcements
Zhaoke Ophthalmology Renews Related-Party CMO Deal for Eyprotor
3M ago
6622
Zhaoke Ophthalmology Sets 2026 AGM to Seek Share Repurchase and Issuance Mandates
Premium
Company Announcements
Zhaoke Ophthalmology Sets 2026 AGM to Seek Share Repurchase and Issuance Mandates
3M ago
6622
Zhaoke Ophthalmology Moves to Update Articles for Hybrid Meetings and New HK Rules
PremiumCompany Announcements
Zhaoke Ophthalmology Moves to Update Articles for Hybrid Meetings and New HK Rules
3M ago
6622
Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025
PremiumCompany Announcements
Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025
4M ago
6622
Zhaoke Ophthalmology Schedules Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
Zhaoke Ophthalmology Schedules Board Meeting to Approve 2025 Annual Results
4M ago
6622
Zhaoke Ophthalmology Set to Accelerate Asia-Pacific Launch After Partner’s FDA Approval for Presbyopia Drug
PremiumCompany Announcements
Zhaoke Ophthalmology Set to Accelerate Asia-Pacific Launch After Partner’s FDA Approval for Presbyopia Drug
6M ago
6622
Zhaoke Ophthalmology Expands BRIMOCHOL™ PF Presbyopia Push to Singapore and Vietnam
PremiumCompany AnnouncementsZhaoke Ophthalmology Expands BRIMOCHOL™ PF Presbyopia Push to Singapore and Vietnam
6M ago
6622
Zhaoke Ophthalmology’s Pediatric Myopia Drug Accepted for Evaluation by Australia’s TGA
Premium
Company Announcements
Zhaoke Ophthalmology’s Pediatric Myopia Drug Accepted for Evaluation by Australia’s TGA
6M ago
6622
Zhaoke Ophthalmology Partners with TSH Biopharm for Taiwan Market Entry
Premium
Company Announcements
Zhaoke Ophthalmology Partners with TSH Biopharm for Taiwan Market Entry
7M ago
6622
Zhaoke Ophthalmology Gains Key Approvals for Innovative Eye Treatments
PremiumCompany Announcements
Zhaoke Ophthalmology Gains Key Approvals for Innovative Eye Treatments
8M ago
6622
Zhaoke Ophthalmology Expands into Indonesia with New Distribution Agreement
PremiumCompany Announcements
Zhaoke Ophthalmology Expands into Indonesia with New Distribution Agreement
8M ago
6622
Zhaoke Ophthalmology Grants 8 Million Share Options to Boost Talent Retention
PremiumCompany Announcements
Zhaoke Ophthalmology Grants 8 Million Share Options to Boost Talent Retention
10M ago
6622
Zhaoke Ophthalmology Reports Significant Revenue Decline and Increased Losses in H1 2025
PremiumCompany Announcements
Zhaoke Ophthalmology Reports Significant Revenue Decline and Increased Losses in H1 2025
11M ago
6622
Zhaoke Ophthalmology Ltd. Schedules Board Meeting for Interim Results
PremiumCompany AnnouncementsZhaoke Ophthalmology Ltd. Schedules Board Meeting for Interim Results
11M ago
6622
Zhaoke Ophthalmology Secures Certification for Innovative Glaucoma Device
Premium
Company Announcements
Zhaoke Ophthalmology Secures Certification for Innovative Glaucoma Device
12M ago
6622
Zhaoke Ophthalmology Secures FDA Orphan Drug Designation for Pediatric Eye Cancer Treatment
Premium
Company Announcements
Zhaoke Ophthalmology Secures FDA Orphan Drug Designation for Pediatric Eye Cancer Treatment
12M ago
6622

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >